Concarlo Therapeutics Presents Novel Therapeutic Approach for ER+ Metastatic Breast Cancer Targeting the CDK Pathway See more here
Read More
Concarlo Therapeutics Hires Vadim Shepel as Chief Business & Operating Officer, Completing Build-out of Company's Core Executive Team Senior Leader Brings Deep Biotech and Pharmaceutical Industry Experience See more here
Read More
Concarlo Expands Executive Leadership Team with the Appointment of Dr. Krishna Allamneni as Chief Development Officer Industry veteran will help accelerate Company's drive to create transformative therapies for drug resistant cancers by controlling the p27 target See more here
Read More